Atrial fibrillation

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter